News & Updates
Filter by Specialty:
Enzalutamide plus radium-223 improves rPFS in mCRPC
First-line treatment with enzalutamide plus radium-223 (Ra223) results in significant improvements in radiological progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the EORTC 1222/PEACE-3 trial have shown.
Enzalutamide plus radium-223 improves rPFS in mCRPC
12 Sep 2025
TALENTACE supports atezolizumab + bevacizumab after TACE for HCC
Findings from the TALENTACE trial presented at ESMO GI 2025 support the combination of atezolizumab and bevacizumab after transarterial chemoembolization (TACE) for the treatment of individuals with systemically untreated, intermediate-to-high tumour burden, unresectable hepatocellular carcinoma (HCC).
TALENTACE supports atezolizumab + bevacizumab after TACE for HCC
12 Sep 2025
Common blood test predicts which AD patients will have rapid cognitive decline
Insulin resistance, detected through the routine triglyceride-glucose (TyG) index, identifies individuals with early Alzheimer’s disease (AD) who are four times more likely to experience rapid cognitive decline, findings from a new study presented at EAN 2025 suggest.
